As the founder of one of Spain’s most active leading investors, Clara is a leading voice in the country’s life sciences sector.
AMGEN is the 9th most valuable Biotech company in the world, with Fina being responsible for the firm’s operations in Iberia.
With 26 years of experience in the Pharma Industry, José is currently VP of Innovation at Grifols, the major biotech company in Spain.
Former Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA) and currently in charge of DDR’s regulatory department in Europe.
Robert leads Biocat’s efforts in consolidating Catalonia as one of the most important healthcare innovation hubs in Europe.
The health expenditure of all Spanish-speaking markets is worth $276B. This is a market too big to avoid, and Catalonia is the gateway to make it happen for your company. Growing life sciences business requires specific talent and often labs, two key assets that the Barcelona-Catalonia BioRegion can offer at incredibly efficient rates.
Catalonia Trade and Investment will select 10 companies that will receive VIP support to land in Barcelona-Catalonia. The main stages of the programme are:
Spain is the 2nd biggest investor in Latin America, has a large network of Double Taxation Agreements and benefits from an extremely tax-efficient holding regime to structure investments in the region.
Catalonia hosts 12 of the largest life sciences global companies, and concentrates over 50% of Spanish pharma and biotech activity. Spain ranks 4th worldwide in number of clinical trials, half of them being conducted in Catalonia.
Barcelona is the 1st Science City in the South of Europe (Nature Index, 2020), with 94 life sciences organizations, 800 research groups and 25,000 researchers.
Barcelona’s operating costs are 29.7% lower than in other top European life sciences clusters (fDi Intelligence), which contributed to a tenfold increase in investment since 2010.